News Information
Focusing on cutting-edge technology and conveying industry voices
In recent years, the influence of machine learning (ML) in the field of protein science has expanded rapidly. From the structural‑prediction revolution sparked by AlphaFold to various sequence‑generation models used for protein design, algorithms are exploring the protein sequence space at an unprecedented pace. However, a persistent challenge remains: while algorithms can “generate hypotheses,” the quality and functionality of proteins still require validation through experimental data. Particularly in enzyme engineering and functional protein optimization, ML models place increasingly stringent demands on training datasets—requiring not only large volumes but also accurate representations of functional diversity. Traditional workflows that rely on cellular expression, purification, and kinetic characterization are often time‑consuming and limited in throughput, frequently becoming bottlenecks in the iterative cycle of ML development. Against this backdrop, a study published by Thornton et al. in ACS Synthetic Biology offers a highly representative approach to addressing these challenges:
2026/03/06
GLP1R (Glucagon-like peptide-1 receptor), known in Chinese as the “glucagon-like peptide‑1 receptor,” is a G protein–coupled receptor (GPCR). This receptor is predominantly expressed in pancreatic β cells, the gastrointestinal tract, and the brain, with particularly critical expression in pancreatic β cells. Functionally, GLP1R serves as the specific receptor for glucagon-like peptide‑1 (GLP‑1). When GLP‑1—a gut‑derived incretin secreted by intestinal L cells—binds to GLP1R, it activates downstream signaling pathways, such as the cAMP/PKA pathway, thereby promoting insulin synthesis and secretion, inhibiting glucagon release, and delaying gastric emptying. Moreover, GLP‑1 signaling enhances the proliferation of pancreatic β cells while suppressing their apoptosis, thus playing a central role in maintaining glucose homeostasis.
2026/02/24
Unnatural amino acids (UAAs) technology expands the genetic code, enabling researchers to incorporate chemically distinct functional groups into proteins—groups that do not occur in nature—thereby offering unprecedented opportunities for protein labeling, structural analysis, modulation of catalytic activity, and the design of novel materials [1]. As the UAA toolbox continues to grow, this approach is emerging as a pivotal technological platform in structural biology, protein engineering, and biopharmaceutical development.
2026/02/02
From January 15 to 17, the second “Science and Innovation · Liuye Lake” Synthetic Biology Manufacturing Innovation and Entrepreneurship Competition was successfully held in Changde, Hunan. After multiple rounds of intense competition and rigorous expert evaluation, Suzhou Perotin Biotechnology Co., Ltd. (hereinafter referred to as “Perotin Bio”) stood out among 338 high‑quality entries from around the world, winning the “Most Promising Award” thanks to its cutting‑edge technological breakthroughs in cell‑free protein expression and significant industrialization potential. This achievement underscores the company’s robust innovative capabilities and highlights the vibrant vitality of China’s synthetic biology sector.
2026/01/26
As the 11th E‑Trade Bio Industry Exhibition (BIOCHINA 2026) draws near, the event has officially announced the highly anticipated list of “Popular Products & Services.” Among numerous entries, Perotin Bio stood out and was proudly selected.
2026/01/19
From December 26 to 28, 2025, the “2025 Third Advanced Enzyme Engineering and Enzyme Technology Applications Conference,” hosted by the Pharmaceutical Chemicals Professional Committee of the China Chemical Enterprise Management Association and organized by the Zhongke Kaisheng (Beijing) Institute of Chemical Technology, was grandly held in Hangzhou. With the core mission of advancing innovation in enzyme engineering technologies and their industrial implementation, the conference brought together leading industry experts, corporate representatives, and researchers from academic and research institutions, fostering in-depth discussions on key topics such as enzyme molecular design, process optimization, and cross‑disciplinary applications.
2026/01/09
In the modern pharmaceutical industry, most small-molecule drug discovery efforts rely on natural products, which are regarded as the most efficient source of new therapeutics. Many life-saving drugs originate from nature, including steroids, polyketides, nonribosomal peptides, terpenes, and alkaloids. Traditionally, natural products have been obtained through two main approaches: production in heterologous hosts or chemical synthesis. However, both methods often face challenges such as low efficiency, long timelines, and high costs. For example, paclitaxel (Taxol), an important anticancer agent, requires first synthesizing its precursor in cell cultures and then carrying out subsequent organic transformations—a process that is both laborious and expensive.
2026/01/09
免费试用 | 从靶点到药物：珀罗汀全长4次跨膜Claudin-6蛋白，成实体瘤靶向研发“关键利器”
Claudin‑6 is a member of the tight junction protein family, containing four transmembrane domains. It plays an important role during embryonic development and is expressed in fetal tissues such as the stomach, pancreas, lung, and kidney. It is one of the earliest epithelial fate‑determining proteins to be expressed in embryonic stem (ES) cells and serves as a cell‑surface–specific marker for human pluripotent stem cells (HPSCs).
2025/12/24
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
